|
|
- For a short-term investment strategy, the company has poor fundamentals.
|
|
|
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
|
|
|
- The group usually releases earnings worse than estimated.
- The company's enterprise value to sales, at 4.35 times its current sales, is high.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
|
|
|
|
|
| Sector Pharmaceuticals - NEC |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | NOVARTIS AG | 2.24% | 218 823 | |
| |
|
|
|
|
Novartis : buys neuroscience company Cadent for up to $770 million |
|
NOVARTIS AG
Back to basics |
| Sales 2020 |
49 153 M
-
-
|
| Net income 2020 |
8 211 M
-
-
|
| Net Debt 2020 |
19 211 M
-
-
|
| P/E ratio 2020 |
26,2x |
| Yield 2020 |
3,28% |
|
| Capitalization |
219 B
219 B
-
|
| EV / Sales 2020 |
4,85x |
| EV / Sales 2021 |
4,44x |
| Nbr of Employees |
110 000 |
| Free-Float |
86,4% |
|
Upcoming event on NOVARTIS AG
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
|
| Growth (Revenue) |
|
| Valuation |
|
| Finances |
|
| Profitability |
|
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
|
| Potential |
|
| Yield |
|
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
